JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Aandelen Lijst・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Gesloten

1.54 -3.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.54

Max

1.56

Belangrijke statistieken
By Trading Economics
Inkomsten	23T 23T
Werknemers	8
EBITDA	1.1T 1.1T

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+243.75% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-193M 107M
Vorige openingsprijs	4.68
Vorige sluitingsprijs	1.54

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.9 / 2.65 Steun & Weerstand

Aldeyra Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mrt 2026, 13:34 UTC

Belangrijke Marktbewegers

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16 dec 2025, 11:43 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Peer Vergelijking

Prijswijziging

Aldeyra Therapeutics Inc Prognose

Koersdoel

By TipRanks

243.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.5 USD 243.75%

Hoogste 9 USD

Laagste 2 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aldeyra Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Aldeyra Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.9 / 2.65Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.